We are a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists, or hem/oncs. Our highly trained group of hematopathologists, or hempaths, utilizes sophisticated diagnostic technologies to provide a differentiated, specialized and integrated assessment of a patient’s condition, aiding hem/oncs in making vital decisions concerning the treatment of malignancies of the blood and bone marrow, and other forms of cancer. , are designed to meet the specific needs of community-based hem/oncs. Our COMPASS service offering includes the determination by our hempaths of the appropriate diagnostic tests to be conducted and the performance of these tests. We then evaluate, synthesize and summarize the results into an easy to read comprehensive report, and our hempaths are available to interpret these results jointly with the hem/onc, giving them the benefit of our expertise and analytical experience. Our CHART service offering combines multiple COMPASS assessments and analyses of disease progression after intervening clinical action, providing the hem/onc with a valuable diagnostic tool to track both a patient’s disease and response to the hem/onc’s prescribed treatment regimen over time.
![Genoptix logo](https://files.capedge.com/S-1/0001047469-07-005948/g1031026.jpg)
Company profile
Ticker
GXDX
Exchange
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
7 Mar 11
25-NSE
Exchange delisting
7 Mar 11
SC 14D9/A
Tender offer solicitation (amended)
7 Mar 11
SC TO-T/A
Third party tender offer statement (amended)
7 Mar 11
8-K
Changes in Control of Registrant
2 Mar 11
SC 14D9/A
Tender offer solicitation (amended)
28 Feb 11
SC TO-T/A
Third party tender offer statement (amended)
28 Feb 11
SC 14D9/A
Tender offer solicitation (amended)
22 Feb 11
SC TO-T/A
Third party tender offer statement (amended)
22 Feb 11
SC 14D9/A
Tender offer solicitation (amended)
7 Feb 11